EQS-News: Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Radioisotope Supply and Contract Development and Manufacturing of Bicycle Radio Conjugates

Berlin, Germany, 27 February 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), a leading provider of isotope technology for medical, scientific, and industrial use, today announced a comprehensive strategic partnership with Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology. Under the agreement, Eckert & Ziegler will supply various radioisotopes and will develop as well as manufacture Bicycle Therapeutics’ radiopharmaceutical molecules, called Bicycle^® Radio Conjugates (BRC^® molecules).

Bicycle Therapeutics’ proprietary molecules, known for their small size and unique structure, are designed to precisely and selectively deliver a range of therapeutic payloads to their chosen targets, engage targets previously considered inaccessible by conventional therapeutic approaches and therefore address significant unmet medical needs in patients. Eckert & Ziegler's state-of-the-art GMP facility in Berlin will play a key role in ensuring the high-quality manufacture and reliable supply of Bicycle Therapeutics’ BRC molecules for clinical trials.

“We are delighted to enter into such a comprehensive partnership with Bicycle Therapeutics, whose innovative science is being used to develop promising radiopharmaceutical molecules,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “Together, we aim to advance the future of radiopharmaceuticals by combining our CDMO and isotopes expertise with Bicycle Therapeutics’ cutting-edge technology.”

“With Eckert & Ziegler, we have found a leading and reliable industry partner with extensive expertise in the development and GMP-compliant manufacturing of radiopharmaceuticals,” said Mike Hannay, D.Sc., FRPharmS, Chief Product and Supply Chain Officer of Bicycle Therapeutics. “Eckert & Ziegler’s advanced capabilities and global reach make them the ideal partner to manufacture BRC molecules as we plan to initiate our first radiopharmaceutical clinical trial next year and continue to seek to leverage the power of our technology platform in areas where we can have the most impact for patients.”

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.com / karolin.riehle@ezag.com
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com